# Patient Blood Management Market

> Patient Blood Management Market Research Report Information By Product (Instruments, Accessories, Reagents and Kits, Software), By Component (Whole Blood, Plasma), By End-User (Blood Banks, Hospitals, Diagnostic Clinics, Pathology Labs), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.38%
- **2025:** USD 15.42 Billion
- **2035:** USD 28.76 Billion
- **Key Players:** Haemonetics Corporation, Terumo Corporation (Terumo Blood and Cell Technologies), Fresenius Kabi, Grifols, Werfen, F. Hoffmann-La Roche, Abbott Laboratories, Siemens Healthineers

**Report ID:** MRFR/HC/7326-HCR · **Pages:** 112 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** October 14, 2026

**URL:** https://www.marketresearchfuture.com/reports/patient-blood-management-market-8798

---

## Market Summary

## Patient Blood Management Market Summary

The Patient Blood Management Market was valued at USD 15.42 Billion in 2025 and is projected to reach USD 16.48 Billion in 2026, climbing to USD 28.76 Billion by 2035 at a CAGR of 6.38% over the forecast period. Two catalysts anchor this trajectory. The World Health Organization's 2025 guidance positions blood management as a health-system priority rather than a laboratory function [1], and value-based payment programs such as the U.S. Hospital Value-Based Purchasing Program tie reimbursement to complication and readmission outcomes that transfusion practice directly influences [3].

Hospitals are moving away from reflexive, threshold-driven transfusion toward protocol-led care built on automated blood analyzers, cell salvage systems, viscoelastic point-of-care testing, and transfusion decision-support software. The economic logic is well documented: activity-based costing places the true cost of a transfused red cell unit at USD 522–1,183 once administration, testing, and complications are included [5], and Western Australia's system-wide program cut red cell use by 41% while saving AUD 80–100 million in activity-based costs [6]. Within the Patient Blood Management Market, that evidence is shifting procurement from blood product volume toward instruments, reagents, and analytics that prevent unnecessary transfusion.

North America leads with a 36.9% share in 2025, supported by accreditation standards and mature stewardship programs [4]. Asia-Pacific is the fastest-growing region at a 6.8% CAGR, driven by surgical capacity expansion and rising anemia screening. Europe ranks second with a 27.5% share, underpinned by the EU's new Substances of Human Origin regulation [11]. Over the next decade, the Patient Blood Management Market will reward vendors that can prove measurable reductions in transfusion rates, length of stay, and episode cost.

## Key Report Takeaways

### • By End-user

- Blood banks held a 53.4% share of the Patient Blood Management Market in 2025, reflecting automation upgrades and expanding donor screening requirements
- Hospitals & clinics generated USD 4.71 billion in 2025 as surgical volumes and protocol integration deepened
- Diagnostic centers & laboratories are projected to expand at an 8.1% CAGR as anemia testing moves into outpatient settings

### • By Region

- North America accounted for 36.9% of the Patient Blood Management Market in 2025
- Asia-Pacific is forecast to grow at a 6.8% CAGR through 2035, the fastest of any region
- Europe captured a 27.5% share, supported by harmonized EU blood and tissue rules

## Market Size and Forecast (2021–2035)

Estimates for the Patient Blood Management Market combine bottom-up modeling of instrument installed bases, reagent pull-through, and software subscriptions with top-down validation against hospital procurement data, national blood utilization surveys [13], and company filings [16][20][21]. Historical values reflect reported revenues and transfusion activity, while forecast values incorporate surgical volume projections, program adoption rates, and reimbursement changes across all five regions.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising volume of complex surgeries | +1.4% | Global | Long-term (≥4 yr) | [8] |
| Value-based reimbursement models | +1.2% | North America, Europe | Medium-term (2–4 yr) | [3] |
| Accreditation and stewardship programs | +0.9% | North America, Europe | Medium-term (2–4 yr) | [4] |
| High prevalence of preoperative anemia | +0.8% | Global, Asia-Pacific | Long-term (≥4 yr) | [9] |
| Constrained blood supply and donor shortages | +0.7% | North America, Europe | Short-term (≤2 yr) | [19] |
| Automation of blood center workflows | +0.6% | Global | Medium-term (2–4 yr) | [15] |

### Rising Volume of Complex Surgeries

Cardiac, orthopedic, oncologic, and trauma procedures account for the largest share of red cell consumption. The Lancet Commission on Global Surgery estimated an unmet need of 143 million additional procedures each year in low- and middle-income countries [8], and procedure counts in high-income systems keep rising with population aging. Each additional high-blood-loss operation raises demand for cell salvage, intraoperative coagulation testing, and preoperative optimization, making surgical growth the most durable driver.

### Value-Based Reimbursement Models

Payers increasingly reimburse outcomes rather than activity. The U.S. Hospital Value-Based Purchasing Program withholds 2% of base operating DRG payments and redistributes them based on quality and efficiency scores [3]. Since transfusion is linked to infection, thrombosis, and longer stays, hospitals see blood management as a direct lever on these scores. Programs reporting up to a 7:1 return on investment strengthen the business case for capital purchases.

### Accreditation and Stewardship Programs

Accreditation converts good intentions into audited practice. The Joint Commission's Patient Blood Management Certification, developed with AABB, requires documented anemia management, transfusion indications, and outcome tracking [4]. Certified hospitals need audit software, standardized testing, and staff training, which raises recurring spend per facility. Yet a 2025 AABB survey found only 46% of institutions worldwide had formal programs [2], leaving substantial room for adoption.

### High Prevalence of Preoperative Anemia

The most controllable risk factor for transfusion is anemia. According to the Global Burden of Disease research, there were 1.92 billion cases of prevalent anemia in 2021 [9], and international consensus guidelines advise treating and screening for anemia well in advance of elective surgery [18]. In spite of this, only 42.6% of North American hospitals evaluated patients undergoing elective surgery for preoperative anemia [2]. The need for iron studies, [hematology analyzers](https://www.marketresearchfuture.com/reports/hematology-analyzers-market-21925), and outpatient anemia clinic workflows is driven by closing that gap.

### Constrained Blood Supply and Donor Shortages

Supply pressure makes conservation a necessity. The American Red Cross declared an emergency blood shortage in January 2024 after donor numbers fell to their lowest level in two decades [19]. The WHO reports wide gaps in donation rates between high- and low-income countries [10]. Hospitals facing rationing adopt cell salvage, restrictive thresholds, and real-time inventory analytics to protect supply for patients who need it most.

### Automation of Blood Center Workflows

Blood centers are replacing manual component separation with automated systems that improve yield and consistency. Terumo Blood and Cell Technologies' 2024 launch of the Reveos Automated Blood Processing System shows how a single platform can process whole blood into multiple components in one step [15]. Automation reduces labor dependence, supports traceability under new regulations [11], and generates recurring demand for disposables and processing sets.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on growth. They overlap with each other and with the drivers, and should not be summed against the overall CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of instruments | −0.9% | Emerging markets | Medium-term (2–4 yr) | [16] |
| Uneven program adoption and clinician inertia | −0.7% | Global | Long-term (≥4 yr) | [2] |
| Shortage of trained transfusion staff | −0.6% | Global | Medium-term (2–4 yr) | [13] |
| Limited reimbursement for PBM services | −0.5% | Asia-Pacific, South America, MEA | Long-term (≥4 yr) | [12] |
| Software interoperability barriers | −0.4% | North America, Europe | Short-term (≤2 yr) | [7] |

### High Capital Cost of Instruments

Cell salvage systems, viscoelastic analyzers, and automated processing platforms require significant upfront investment plus service contracts. Smaller hospitals in emerging economies struggle to justify these outlays when blood products remain inexpensive at the point of purchase. Vendors increasingly respond with reagent-rental and leasing models [16], but the capital barrier still slows penetration outside tertiary centers.

### Uneven Program Adoption and Clinician Inertia

Practice has not always changed due to evidence alone. Even while less than half of institutions worldwide have official programs [2], many doctors continue to transfuse based on habit or liberal standards. It takes years to develop feedback loops, leadership, and audits in order to change behavior. Reorder rates for consumables are weakened when champions are absent and purchased equipment is underutilized.

### Shortage of Trained Transfusion Staff

Blood banks and laboratories face persistent workforce gaps. U.S. national utilization surveys document vacancies among medical laboratory scientists and transfusion safety officers [13]. Without dedicated coordinators, hospitals cannot run anemia clinics, monitor transfusion indications, or maintain certification. Staffing shortfalls cap the number of programs that can launch each year, regardless of available funding.

### Limited Reimbursement for PBM Services

Most health systems pay for blood products and transfusion procedures but not for the coordination work that avoids them. European Commission guidance noted that funding models rarely reward prevention [12]. In Asia-Pacific, South America, and the Middle East and Africa, the absence of dedicated tariffs leaves hospitals to absorb program costs, delaying investment in screening and analytics.

### Software Interoperability Barriers

Clean data from laboratory systems, blood bank software, and electronic health records is essential for transfusion decision-support tools. Vendor integration is still expensive and time-consuming. Strong results are shown in studies of multimodal programs when data flows freely [7], but many hospitals' fragmented IT stacks limit the utility of analytics purchases and cause deployment delays.

## Opportunities

## Patient Blood Management Market Opportunities

### Program Rollouts in Emerging Health Systems

WHO's 2025 guidance gives ministries a blueprint for national programs [1], and countries with high anemia burden stand to gain most [9]. India's PM-JAY insurance scheme, which funds surgical care for hundreds of millions of beneficiaries [22], is expanding the base of procedures that benefit from screening and conservation. Vendors offering low-cost analyzers and training bundles can establish early positions in the Patient Blood Management Market across these systems.

### Data Analytics and Outcome-Based Service Models

Hospitals are looking for evidence of outcomes rather than just equipment. Recurring subscription revenue is generated by analytics solutions that benchmark transfusion appropriateness, correlate it with duration of stay, and report savings. A few suppliers are looking at outcome-based contracts, in which costs are dependent on confirmed decreases in blood usage. This paradigm supports value-based payment and compensates suppliers with robust data assets.

### Outpatient Anemia Clinics and Surgical Prehabilitation

Moving anemia diagnosis and intravenous iron therapy into pre-surgical clinics allows treatment weeks before an operation. These clinics need point-of-care hemoglobin testing, iron panels, and scheduling software. Diagnostic centers and outpatient providers are well placed to capture this demand, supporting the fastest growth among end users.

### AI-Driven Transfusion Decision Support

Machine learning models can predict bleeding risk, flag inappropriate orders, and forecast blood demand at the hospital level. Embedding such tools in order-entry workflows reduces unnecessary transfusions without adding clinician burden. Early adopters gain both clinical and inventory benefits, creating a premium software tier.

### Bloodless Medicine and Specialized Care Pathways

Dedicated bloodless medicine centers, originally built for patients who decline transfusion, have become testing grounds for broader blood conservation strategies. Their protocols translate well to oncology, obstetrics, and pediatric surgery, where minimizing donor exposure carries clinical value. Vendors that package these pathways for wider use can open new service lines.

## Future Outlook

## Patient Blood Management Market Future Outlook

### AI and Predictive Transfusion Management

Predictive models will move from pilot to routine use, flagging high-bleeding-risk patients before surgery and forecasting hospital-level blood demand. Integration with order entry will make restrictive practice the default rather than a policy reminder. Vendors with large outcome datasets will gain an edge, and software will play a larger role in shaping the Patient Blood Management Market than its revenue share suggests.

### Value-Based Contracting and Platform Economics

Suppliers will increasingly bundle instruments, reagents, software, and consulting into multi-year contracts linked to outcomes. This shifts competition from hardware specifications to verified savings. Programs delivering documented reductions in transfusion and complications [7] will set the reference for procurement, favoring broad-portfolio companies.

### Demographics and Blood Supply Resilience

The UN projects the population aged 65 and older will more than double to about 1.6 billion by 2050 [14]. Older patients undergo more surgery and carry higher anemia rates, while the donor pool shrinks relative to demand. This imbalance will make perioperative blood management a structural requirement for health systems rather than an optional quality initiative.

### Sustainability and Waste Reduction

Hospitals are beginning to count blood product wastage within sustainability and efficiency reporting. Expired units, discarded components, and avoidable transfusions represent both cost and resource loss. Inventory analytics and automated processing that reduce wastage will gain priority as health systems set waste-reduction targets.

## Segment Insights

## Patient Blood Management Market Segmentation

Segmentation of the Patient Blood Management Market follows end-user demand, reflecting where instruments, reagents, and software are purchased and used.

### By End-user

Within the Patient Blood Management Market, end-user segmentation separates [blood collection](https://www.marketresearchfuture.com/reports/blood-collection-market-7013) and processing demand from clinical and diagnostic demand.

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Clinics | USD 4.71 Billion | Surgical volume growth and protocol integration |
| Blood Banks | 53.4% share | Automation upgrades and donor screening requirements |
| Diagnostic Centers & Laboratories | 8.1% CAGR | Outpatient anemia and coagulation testing |
| Others | 7.4% CAGR | Ambulatory surgery centers and outpatient programs |

Blood banks lead because they purchase high-value processing systems, donor screening assays, and disposables at scale, and the 2024 Reveos launch shows continuing automation investment [15]. Hospitals & clinics rank second, driven by cell salvage, viscoelastic testing, and protocol software tied to accreditation. Diagnostic centers & laboratories grow fastest as anemia screening shifts to outpatient settings. The others category, including ambulatory surgery centers, expands as blood management protocols follow procedures out of the hospital.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 36.9% share | Accreditation, value-based payment, viscoelastic testing |
| Europe | 27.5% share | SoHO compliance, national PBM programs, blood center automation |
| Asia-Pacific | 6.8% CAGR | Surgical capacity growth, anemia screening, blood bank modernization |
| South America | USD 0.93 Billion | Public blood network upgrades, donor screening |
| Middle East & Africa | 5.9% CAGR | Hospital construction, blood safety programs |
| Total | USD 15.42 Billion | — |

Regional demand in the Patient Blood Management Market tracks surgical capacity, accreditation maturity, and reimbursement design. North America and Europe hold the largest installed bases, while Asia-Pacific supplies the strongest incremental growth.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 84.6% share of region | CMS value-based programs and Joint Commission certification |
| Canada | 6.1% CAGR | Provincial transfusion stewardship networks |
| Mexico | USD 0.39 Billion | Private hospital expansion and IMSS modernization |

The United States dominates regional spend, transfusing roughly 10.7 million red cell units annually [13]. Hospital Value-Based Purchasing [3] and Joint Commission certification [4] make transfusion appropriateness a reportable metric, and the January 2024 national shortage declaration [19] reinforced conservation as an operational priority. Canada's provincial networks emphasize audit and restrictive thresholds, while Mexico's demand rises with private surgical capacity.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 22.4% share of region | Hospital reform and national PBM network |
| UK | 6.0% CAGR | NHS national comparative transfusion audits |
| France | USD 0.61 Billion | Centralized blood establishment automation |
| Italy | 11.2% share of region | National Blood Centre PBM guidance |
| Spain | 5.7% CAGR | Regional health system stewardship programs |
| Nordic Countries | USD 0.29 Billion | Digital health integration |
| Russia | 5.1% share of region | Domestic blood service upgrades |
| Rest of Europe | 5.0% CAGR | EU-funded capacity building |

Regulation (EU) 2024/1938 on Substances of Human Origin replaces older blood and tissue directives with stricter traceability, donor protection, and quality rules [11]. Blood establishments must upgrade processing and data systems to comply, supporting automation demand. Germany and Italy have mature national programs built on European Commission guidance [12], while the UK relies on audit-driven practice change within the NHS.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 31.8% share of region | Tertiary hospital expansion and blood bank digitization |
| India | 8.9% CAGR | PM-JAY surgical coverage and anemia burden |
| Japan | USD 0.86 Billion | Aging population and high surgical intensity |
| South Korea | 7.9% share of region | Advanced hospital IT and point-of-care testing |
| ASEAN | 7.6% CAGR | Private hospital investment and blood safety reforms |
| Rest of Asia-Pacific | USD 0.31 Billion | Australia's established PBM standards |

Asia-Pacific is the growth engine of the Patient Blood Management Market. China's hospital build-out and India's insurance-funded surgical growth [22] expand the procedure base, while high anemia prevalence [9] makes screening a priority. Japan's demographic profile sustains surgical demand, and Australia's national standards, proven in Western Australia's program [6], serve as a regional template.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 52.7% share of region | Public hemocenter network modernization |
| Argentina | 5.8% CAGR | Private hospital investment |
| Rest of South America | USD 0.22 Billion | Donor screening upgrades |

Brazil's public hemocenter network anchors regional demand, with investment directed at automated processing and donor testing. Argentina's private hospitals are adopting viscoelastic testing in cardiac and trauma care. Limited reimbursement for coordination services [12] remains the main barrier, so growth concentrates in procurement of instruments and disposables rather than software.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.4% share of region | Vision 2030 hospital investment |
| UAE | 7.1% CAGR | Accredited private hospitals and medical tourism |
| South Africa | USD 0.13 Billion | National blood service modernization |
| Egypt | 9.6% share of region | Universal health insurance rollout |
| Rest of MEA | 4.9% CAGR | WHO blood safety programs |

Gulf states lead regional spending through large hospital construction programs and international accreditation requirements. Saudi Arabia and the UAE are early adopters of formal stewardship programs. Across sub-Saharan Africa, WHO blood safety initiatives [10] focus on supply adequacy and testing, creating long-term demand for screening reagents and basic processing equipment.

## Competitive Benchmarking

## Competitive Benchmarking

The Patient Blood Management Market is moderately concentrated, with an estimated HHI of 900–1,200. The top five players hold an estimated 45–52% combined share, with leadership split between blood processing specialists and diagnostics majors. Regional distributors and niche software providers fragment the remaining market.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Haemonetics Corporation | ~10–13% | Cell salvage, TEG viscoelastic testing, apheresis | Hospital-focused hemostasis leader |
| Terumo Corporation (Terumo Blood and Cell Technologies) | ~9–12% | Automated whole blood processing, apheresis | Blood center automation specialist |
| Fresenius Kabi | ~7–10% | Blood bags, apheresis, autotransfusion | Broad transfusion consumables portfolio |
| Grifols | ~7–9% | Blood typing, NAT donor screening | Integrated donor testing and plasma |
| Werfen | ~6–9% | Hemostasis analyzers, ROTEM, immunohematology | Hemostasis and transfusion diagnostics |
| F. Hoffmann-La Roche | ~6–8% | Donor screening, hematology, coagulation assays | High-throughput diagnostics |
| Abbott Laboratories | ~4–6% | Blood screening, hematology analyzers | Laboratory automation and screening |
| Siemens Healthineers | ~3–5% | Hemostasis and hematology systems | Integrated lab platforms |
| Bio-Rad Laboratories | ~3–5% | Immunohematology reagents, blood typing | Reagent-focused specialist |
| LivaNova | ~2–4% | Autotransfusion systems for cardiac surgery | Cardiac surgery niche |

## Recent News & Developments

## Recent News & Developments

Recent activity across the Patient Blood Management Market centers on supply resilience, automation, regulation, and consolidation.

- American Red Cross (January 2024): Declared an emergency blood shortage after donor numbers reached a 20-year low, intensifying hospital focus on conservation [19]

- European Union (July 2024): Published Regulation (EU) 2024/1938 on Substances of Human Origin, tightening traceability and quality rules for blood establishments [11]
- CMS (August 2024): Finalized FY2025 inpatient payment rules maintaining value-based purchasing adjustments tied to outcomes [3]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Instruments, accessories, reagents and kits, and software used to manage patient blood across hospitals and clinics, blood banks, diagnostic centers and laboratories, and other care settings |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 15.42 Billion |
| Market Size in 2035 | USD 28.76 Billion |
| CAGR (2026–2035) | 6.38% |
| Fastest Growing Segments | Diagnostic Centers & Laboratories (8.1% CAGR); Others (7.4% CAGR); Asia-Pacific (6.8% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Haemonetics Corporation, Terumo Corporation, Fresenius Kabi, Grifols, Werfen, F. Hoffmann-La Roche, Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories, LivaNova |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What procurement criteria matter most when buying solutions in the Patient Blood Management Market?**
A: Buyers should weigh total cost of ownership, including reagents and service, against documented reductions in transfusion and length of stay. Contracts with outcome reporting built in give finance teams evidence for renewal [16].

**Q: Does viscoelastic testing offer faster payback than conventional coagulation panels?**
A: In cardiac and trauma surgery, usually yes. Viscoelastic results arrive within minutes, guiding targeted component therapy and cutting plasma and platelet use that standard lab panels often fail to prevent in time [7].

**Q: How does accreditation influence vendor selection in the Patient Blood Management Market?**
A: Certified hospitals must produce audit-ready transfusion data, so they favor vendors whose systems export indication and outcome reports directly. Suppliers lacking reporting tools face exclusion from shortlists [4].

**Q: What is the biggest integration hurdle for transfusion software?**
A: Mapping laboratory, blood bank, and health record data into consistent fields is the main obstacle. Hospitals should budget for interface work and data governance before go-live, not after [13].

**Q: Which emerging use cases could add revenue in the Patient Blood Management Market?**
A: Obstetric hemorrhage protocols and oncology anemia pathways are early candidates. Both involve frequent transfusion, measurable outcomes, and clinical teams receptive to structured screening and point-of-care testing in the Patient Blood Management Market [18].

**Q: How do bloodless medicine programs affect wider hospital demand?**
A: Bloodless centers prove that complex surgery can proceed with minimal transfusion. Their success persuades hospital leadership to extend the same protocols system-wide, expanding purchases of salvage and monitoring equipment [6].

**Q: What consolidation trend should investors expect?**
A: Diagnostics groups are acquiring transfusion and hemostasis specialists to offer end-to-end portfolios. Werfen's move for Immucor illustrates this pattern, and further deals targeting software and point-of-care assets are likely [17].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/patient-blood-management-market-8798*